A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.

• Phase: Phase 3

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Thyrotropin-Releasing Hormone

Criteria

Inclusion Criteria:

• Japanese SCD patients with mild to moderate ataxia

Exclusion Criteria:

• Patients with secondary ataxia

• Patients with clinically significant hepatic, renal, or cardiovascular dysfunction